A Phase II Trial of Patients With Limited Stage Small Cell Lung Cancer Treated With Thoracic Radiation Therapy and Chemotherapy With Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines

Trial Profile

A Phase II Trial of Patients With Limited Stage Small Cell Lung Cancer Treated With Thoracic Radiation Therapy and Chemotherapy With Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2012

At a glance

  • Drugs Anti-idiotype cancer vaccine Titan Pharmaceuticals (Primary) ; Anti-idiotype GD2 cancer vaccine 1A7 (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2012 Actual patient number 9 added as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Planned end date 1 May 2003 added as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top